Literature DB >> 19432523

Growth inhibitory action of ebselen on fluconazole-resistant Candida albicans: role of the plasma membrane H+-ATPase.

Blase Billack1, Michelle Santoro, Cesar Lau-Cam.   

Abstract

PMA1 is a yeast gene that codes for the plasma membrane H(+)-ATPase, a protein commonly referred to as Pma1p. Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) is a synthetic selenium-containing compound that has recently been shown to display antimicrobial activity owing to its ability to inhibit Pma1p. Ebselen is able to block the activity of Pma1p not only in opportunistic pathogens such as Cryptococcus neoformans and Candida albicans but also in nonpathogenic yeasts such as Saccharomyces cerevisiae. A series of in vitro studies aimed at evaluating the antifungal activity of ebselen were performed. At low concentrations (<10 microM), ebselen was fungistatic against three strains of S. cerevisiae (IC(50) approximately 3 microM) and one fluconazole-resistant strain of C. albicans (IC(50) approximately 6 microM), and at a high concentration (30 microM) it was fungicidal against C. albicans. Moreover, ebselen was found to inhibit medium acidification by the fluconazole-resistant strain of C. albicans in a concentration-dependent manner. In comparison to currently used antifungal agents represented by azole (itraconazole, ketoconazole, fluconazole) and polyene (amphotericin B) compounds, ebselen was at least 10-fold more potent than fluconazole but less active than the other compounds tested. The present results suggest that the growth inhibitory activity of ebselen toward fluconazole-resistant yeast cells is due, at least in part, to inhibition of Pma1p. Ebselen may also serve as a useful agent in the treatment of infections caused by fluconazole-resistant fungi.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432523     DOI: 10.1089/mdr.2009.0872

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  10 in total

1.  High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Authors:  Matthew J Saunders; Steven W Graves; Larry A Sklar; Tudor I Oprea; Bruce S Edwards
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

2.  The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.

Authors:  Ann R Holmes; Mikhail V Keniya; Irena Ivnitski-Steele; Brian C Monk; Erwin Lamping; Larry A Sklar; Richard D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

Review 3.  Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.

Authors:  Gajendra Kumar Azad; Raghuvir S Tomar
Journal:  Mol Biol Rep       Date:  2014-08       Impact factor: 2.316

4.  Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata.

Authors:  Laura Bedin Denardi; Débora Alves Nunes Mario; Erico Silva de Loreto; Cristina Wayne Nogueira; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2013-06-23       Impact factor: 2.574

5.  Carboxyl-ebselen-based layer-by-layer films as potential antithrombotic and antimicrobial coatings.

Authors:  Wenyi Cai; Jianfeng Wu; Chuanwu Xi; Arthur J Ashe; Mark E Meyerhoff
Journal:  Biomaterials       Date:  2011-07-26       Impact factor: 12.479

6.  Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris.

Authors:  Haroldo Cesar de Oliveira; Maria Candida Monteiro; Suélen Andreia Rossi; Javier Pemán; Alba Ruiz-Gaitán; Maria José Soares Mendes-Giannini; Emilia Mellado; Oscar Zaragoza
Journal:  Front Cell Infect Microbiol       Date:  2019-04-02       Impact factor: 5.293

Review 7.  Advances in targeting the vacuolar proton-translocating ATPase (V-ATPase) for anti-fungal therapy.

Authors:  Summer R Hayek; Samuel A Lee; Karlett J Parra
Journal:  Front Pharmacol       Date:  2014-01-27       Impact factor: 5.810

8.  Isolation of native plasma membrane H+-ATPase (Pma1p) in both the active and basal activation states.

Authors:  Jesper Torbøl Pedersen; Tamara Kanashova; Gunnar Dittmar; Michael Palmgren
Journal:  FEBS Open Bio       Date:  2018-03-25       Impact factor: 2.693

9.  Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species.

Authors:  Lin Liu; Tong Jiang; Jia Zhou; Yikun Mei; Jinyang Li; Jingcong Tan; Luqi Wei; Jingquan Li; Yibing Peng; Changbin Chen; Ning-Ning Liu; Hui Wang
Journal:  Microb Biotechnol       Date:  2021-05-06       Impact factor: 5.813

10.  Characterization of the Efflux Capability and Substrate Specificity of Aspergillus fumigatus PDR5-like ABC Transporters Expressed in Saccharomyces cerevisiae.

Authors:  Brooke D Esquivel; Jeffrey M Rybak; Katherine S Barker; Jarrod R Fortwendel; P David Rogers; Theodore C White
Journal:  mBio       Date:  2020-03-24       Impact factor: 7.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.